Organigram Holdings Receives Approval for 150,000 sq. ft. Cultivation Facility | CashCropToday
0 Shares 183 Views

Organigram Holdings Receives Approval for 150,000 sq. ft. Cultivation Facility

February 12, 2018
183 Views

Organigram Holdings (TSXV: OGRMF) has been granted a cultivation license from Health Canada to grow cannabis in the company’s 150,000 sq. ft. facility. The company announced that they have already begun filling the grow rooms with clones and is planning to complete its first harvest at the end of April.  Organigram plans to operate a total of 23 cultivation rooms which will bring the company’s output to 16,000 kg/year.
Greg Engel, appointed to Organigram CEO in March 2017, stated, “As a company, we are steadfast in our commitment to applying technology to the efficient production of exceptional cannabis products,” explains Engel. “Our pursuit of best-in-class processes reflects our commitment to industry leadership and unprecedented customer value.”

Link to Press Release

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
269 views
Market Watch
269 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
192 views
Global
192 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
189 views
Manufacturing
189 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: